104 related articles for article (PubMed ID: 19183192)
1. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
Lapalombella R; Gowda A; Joshi T; Mehter N; Cheney C; Lehman A; Chen CS; Johnson AJ; Caligiuri MA; Tridandapani S; Muthusamy N; Byrd JC
Br J Haematol; 2009 Mar; 144(6):848-55. PubMed ID: 19183192
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide and chronic lymphocytic leukemia.
González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
[TBL] [Abstract][Full Text] [Related]
3. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
Andritsos LA; Johnson AJ; Lozanski G; Blum W; Kefauver C; Awan F; Smith LL; Lapalombella R; May SE; Raymond CA; Wang DS; Knight RD; Ruppert AS; Lehman A; Jarjoura D; Chen CS; Byrd JC
J Clin Oncol; 2008 May; 26(15):2519-25. PubMed ID: 18427150
[TBL] [Abstract][Full Text] [Related]
4. Novel agents for chronic lymphocytic leukemia.
Wu M; Akinleye A; Zhu X
J Hematol Oncol; 2013 May; 6():36. PubMed ID: 23680477
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
Tai YT; Catley LP; Mitsiades CS; Burger R; Podar K; Shringpaure R; Hideshima T; Chauhan D; Hamasaki M; Ishitsuka K; Richardson P; Treon SP; Munshi NC; Anderson KC
Cancer Res; 2004 Apr; 64(8):2846-52. PubMed ID: 15087402
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
Kelley SK; Gelzleichter T; Xie D; Lee WP; Darbonne WC; Qureshi F; Kissler K; Oflazoglu E; Grewal IS
Br J Pharmacol; 2006 Aug; 148(8):1116-23. PubMed ID: 16847437
[TBL] [Abstract][Full Text] [Related]
7. A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo.
Collier-Bain HD; Emery A; Causer AJ; Brown FF; Oliver R; Dutton D; Crowe J; Augustine D; Graby J; Leach S; Eddy R; Rothschild-Rodriguez D; Gray JC; Cragg MS; Cleary KL; Moore S; Murray J; Turner JE; Campbell JP
Brain Behav Immun; 2024 May; 118():468-479. PubMed ID: 38503395
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Zhu D; Corral LG; Fleming YW; Stein B
Cancer Immunol Immunother; 2008 Dec; 57(12):1849-59. PubMed ID: 18392823
[TBL] [Abstract][Full Text] [Related]
9. Chemical tools to monitor and manipulate the adaptive immune system.
Kodadek T
Chem Biol; 2014 Sep; 21(9):1066-74. PubMed ID: 25237855
[TBL] [Abstract][Full Text] [Related]
10. Application of new drugs in chronic lymphocytic leukemia.
Robak T
Mediterr J Hematol Infect Dis; 2010 May; 2(2):e2010011. PubMed ID: 21415964
[TBL] [Abstract][Full Text] [Related]
11. Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications.
Tai YT; Catley LP; Mitsiades CS; Burger R; Podar K; Shringpaure R; Hideshima T; Chauhan D; Hamasaki M; Ishitsuka K; Richardson P; Treon SP; Munshi NC; Anderson KC
Cancer Res; 2024 Mar; 84(6):936. PubMed ID: 38486489
[No Abstract] [Full Text] [Related]
12. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.
Filbert EL; Björck PK; Srivastava MK; Bahjat FR; Yang X
Cancer Immunol Immunother; 2021 Jul; 70(7):1853-1865. PubMed ID: 33392713
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials.
Lu H; Zhou Q; He J; Jiang Z; Peng C; Tong R; Shi J
Signal Transduct Target Ther; 2020 Sep; 5(1):213. PubMed ID: 32968059
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Holstein SA; McCarthy PL
Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024
[TBL] [Abstract][Full Text] [Related]
15. Target Therapy in Hematological Malignances: New Monoclonal Antibodies.
Podhorecka M; Markowicz J; Szymczyk A; Pawlowski J
Int Sch Res Notices; 2014; 2014():701493. PubMed ID: 27433507
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).
Freeman CL; Gribben JG
Curr Hematol Malig Rep; 2016 Feb; 11(1):29-36. PubMed ID: 26857283
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Gribben JG; Fowler N; Morschhauser F
J Clin Oncol; 2015 Sep; 33(25):2803-11. PubMed ID: 26195701
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.
Mittal AK; Chaturvedi NK; Rai KJ; Gilling-Cutucache CE; Nordgren TM; Moragues M; Lu R; Opavsky R; Bociek GR; Weisenburger DD; Iqbal J; Joshi SS
Mol Med; 2014 Jul; 20(1):290-301. PubMed ID: 24800836
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.
Kharfan-Dabaja MA; Wierda WG; Cooper LJ
Leukemia; 2014 Mar; 28(3):507-17. PubMed ID: 24157582
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.
Xu Y; Sun J; Sheard MA; Tran HC; Wan Z; Liu WY; Asgharzadeh S; Sposto R; Wu HW; Seeger RC
Cancer Immunol Immunother; 2013 Oct; 62(10):1637-48. PubMed ID: 23982484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
